A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma.

Piritrexim is a lipid-soluble drug which is as effective an inhibitor of dihydrofolate reductase as methotrexate. Phase I and II studies have indicated activity in some tumour types. Because of its lipophilicity we have conducted a phase II study in recurrent high-grade malignant glioma (grades III...

Descripción completa

Detalles Bibliográficos
Autores principales: Bleehen, N. M., Newman, H. V., Rampling, R. P., Ramsay, J. R., Roberts, J. T., Bedford, P., Nethersell, A. B.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033879/
https://www.ncbi.nlm.nih.gov/pubmed/7669591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033879/
https://www.ncbi.nlm.nih.gov/pubmed/7669591

Ejemplares similares